|
US2019321296A1
|
|
Inhaled aspirin and magnesium to treat inflammation
|
|
WO2019059953A2
|
|
Dry powder compositions with magnesium stearate
|
|
US2018311156A1
|
|
Dry powder inhalation device
|
|
US2017348333A1
|
|
Dry powder formulations for inhalation
|
|
WO2017100656A1
|
|
Dry powder formulations of aspirin for inhalation
|
|
WO2017079397A1
|
|
Dry powder inhalation device
|
|
WO2016176552A1
|
|
Dry power formulations for inhalation
|
|
KR20170039255A
|
|
Dry powder formulations for inhalation
|
|
EP3107548A1
|
|
Dry powder formulations for inhalation
|
|
US2016019473A1
|
|
Arranging transport amongst parties through use of mobile devices
|
|
US2014322328A1
|
|
Dry powder formulations and methods of use
|
|
US2014174440A1
|
|
Dry powder inhaler and methods of use
|
|
US2013310805A1
|
|
Delivery of substances to the external auditory canal and nasal cavity
|
|
US2014174437A1
|
|
Dry powder inhaler and methods of use
|
